Introduction to
FFPE Blocks for Pharma Clinical Trials
Clinically Annotated FFPE Blocks for Pharmaceutical Clinical Trials
Access to reliable FFPE tissue is essential for pharmaceutical companies conducting translational research, biomarker discovery, assay validation, and retrospective clinical trial analysis. We support pharma and biotechnology sponsors with quality-controlled formalin-fixed, paraffin-embedded tumor blocks selected according to protocol-specific inclusion and exclusion criteria. Available specimens may be accompanied by diagnosis, histological subtype, tumor stage, grade, collection date, treatment history, demographic information, and pathology documentation, subject to availability and applicable ethical permissions.
Cohorts can be created for solid tumors including lung, breast, colorectal, gastric, ovarian, pancreatic, prostate, liver, kidney, and other cancer indications. Each request is reviewed to determine tissue availability, tumor content, block age, specimen type, and required clinical annotations. Additional pathology review, H&E preparation, tumor-area marking, macrodissection guidance, and slide sectioning may also be arranged. This structured sourcing approach helps sponsors reduce screening failures, improve study consistency, and obtain FFPE blocks aligned with pharmaceutical clinical trial and biomarker-development objectives.
FFPE Tumor Tissue for Biomarker and Companion Diagnostic Development
FFPE blocks are widely used to develop and validate biomarkers that support patient stratification, drug-response assessment, and companion diagnostic programs. Pharmaceutical research teams may require tissue cohorts selected according to molecular alterations, protein-expression patterns, treatment exposure, clinical outcomes, or disease progression. We can support customized sourcing of FFPE tumor samples associated with biomarkers such as EGFR, KRAS, BRAF, ALK, ROS1, HER2, BRCA1, BRCA2, PIK3CA, MSI, PD-L1, and other study-specific targets, where testing data are available. Samples can be supplied as complete blocks, unstained slides, curls, cores, or sections depending on research requirements and tissue-use permissions.
Â
Cohort design may include biomarker-positive and biomarker-negative groups, responder and non-responder populations, or matched clinical subgroups. Pathology review can help confirm diagnosis, tumor percentage, necrosis, and tissue adequacy before shipment. By combining specimen sourcing with clinical and molecular annotation, we help pharma sponsors create evidence-ready collections for analytical validation, translational studies, exploratory endpoints, and companion diagnostic development.
Retrospective FFPE Cohorts Supporting Clinical Trial Research
Archived FFPE collections can provide pharmaceutical companies with an efficient route to investigate clinical hypotheses without waiting for lengthy prospective recruitment. Retrospective cohorts may be assembled from previously collected diagnostic or surgical specimens, subject to ethical approval, consent status, applicable regulations, and data availability. These cohorts can support trial feasibility assessment, prevalence studies, biomarker validation, assay optimization, and retrospective outcome analysis.
Sponsors may define selection criteria based on indication, stage, histology, treatment-naive status, prior therapy, biomarker status, response category, survival data, or date of collection. Supporting records may include pathology reports, diagnosis, stage, grade, specimen site, procedure type, treatment information, and follow-up data where permitted. Tissue qualification can include H&E review, tumor-content estimation, necrosis assessment, and confirmation of available material. Retrospective FFPE sourcing allows sponsors to evaluate research questions rapidly while preserving the option to expand into prospective or longitudinal collection.
Custom FFPE Block Sourcing for Global Pharma Programs
Every pharmaceutical clinical trial has different tissue, data, regulatory, and logistical requirements. Our custom FFPE sourcing process begins with a detailed review of the study protocol, target indication, number of donors, required specimen format, clinical variables, molecular criteria, and delivery schedule. A feasibility assessment is then performed to determine available cases, anticipated screening requirements, testing gaps, and potential collection timelines. FFPE cohorts can be structured for discovery research, exploratory biomarker analysis, clinical assay development, translational endpoints, and post-trial investigations.
Services may include pathology confirmation, H&E slide preparation, block qualification, tissue sectioning, biomarker testing coordination, de-identification, data harmonization, and shipment planning. Specimens are handled according to approved procedures and applicable ethical and regulatory requirements. Whether a sponsor needs a small pilot cohort or a multi-site collection program, the objective is to provide consistent, traceable, and study-aligned FFPE material.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.